Editor’s note: This round‑up is based on press releases, peer‑reviewed publications, and company communications received in ...

The approval gives Ascendis a window of opportunity to eat into BioMarin's market share, as the latter works on its own ...

The Centers for Medicare & Medicaid Services (CMS) in the US has extended the deadline for companies to take part in its ...

McKinnon discusses ‘white space’ in R&D, about integrating generative and agentic AI with human-in-the-loop oversight while prioritising patient safety and regulatory, and how all this advances health ...

An international group of cancer experts has called for fundamental change to healthcare approaches for bile duct cancer, ...

The advancement of QEL-005 into clinical testing comes shortly after London-headquartered Quell said it was calling a ...

Moderna collaborated closely with its global content partner, Wildtype (an Omnicom Health agency), to validate how AI agents ...

Atrium is led by Kathleen Gallagher, who was chief programme officer at Avidity before it was acquired by Novartis and will ...

Novo Nordisk has said it will invest DKK 3.2 billion (€432 million) in a manufacturing plant in Ireland that will be used to ...

While Global Strategy sets the initial direction, true agility is sustained through a 360-degree loop that prioritises ...

The drug acts as a prostacyclin receptor agonist, which is a fairly crowded class with several approved oral, intravenous, or ...

Specifically, the CHMP has backed conditional marketing authorisation for Ojemda (tovorafenib) as a monotherapy for children ...